Cefepime An Effective Alternative To Carbapenems In Patients With BSIs Caused By C-AmpC β-Lactamase-Producing Enterobacterales, Study Finds

Infectious Disease Advisor (2/4, Nye) reports a study found “cefepime is supported as an alternative to carbapenems in patients with bloodstream infections (BSIs) caused by chromosomal AmpC (c-AmpC) β-lactamase-producing Enterobacterales.” Researchers carried out a systematic review and meta-analysis and found “patients in the cefepime group showed significantly reduced risk of 30-day mortality relative to those who received carbapenems.” The study was published in Infection.